P4–085: The role of liver X receptor (LXR) agonists in modulating Aβ levels <i>In vitro</i> and <i>In vivo</i>
David Riddell(Eli Lilly (United States)), Steve Jacobsen, Tom Comery(Princeton University), Robert H. Ring(Autism Speaks), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter H. Reinhart(University of Massachusetts Amherst), Robert Martone(Princeton University), Yolanda Kirksey(Princeton University), Hua Zhou, Menelas N. Pangalos(AstraZeneca (United Kingdom)), Suzan Aschmies(Princeton University), Jane Kouranova(Princeton University)
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Whole-genome sequencing of quartet families with autism spectrum disorder
|Nature Medicine|2015|540
Detection of Clinically Relevant Genetic Variants in Autism Spectrum Disorder by Whole-Genome Sequencing
|The American Journal of Human Genetics|2013|496
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445